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Abstract
Background: Mammographic density (MD) and malignant-appearing microcalcifications (MAMCs) represent the
earliest mammographic findings of non-palpable breast carcinomas. Matrix proteoglycans versican and decorin are
frequently over-expressed in various malignancies and are differently involved in the progression of cancer. In the
present study, we have evaluated the expression of versican and decorin in non-palpable breast carcinomas and
their association with high risk mammographic findings and tumor characteristics.
Methods: Three hundred and ten patients with non-palpable suspicious breast lesions, detected during screening
mammography, were studied. Histological examination was carried out and the expression of decorin, versican,
estrogen receptor a (ERa), progesterone receptor (PR) and c-erbB2 (HER-2/neu) was assessed by
immunohistochemistry.
Results: Histological examination showed 83 out of 310 (26.8%) carcinomas of various subtypes.
Immunohistochemistry was carried out in 62/83 carcinomas. Decorin was accumulated in breast tissues with MD
and MAMCs independently of the presence of malignancy. In contrast, versican was significantly increased only in
carcinomas with MAMCs (median ± SE: 42.0 ± 9.1) and MD (22.5 ± 10.1) as compared to normal breast tissue with
MAMCs (14.0 ± 5.8), MD (11.0 ± 4.4) and normal breast tissue without mammographic findings (10.0 ± 2.0).
Elevated levels of versican were correlated with higher tumor grade and invasiveness in carcinomas with MD and
MAMCs, whereas increased amounts of decorin were associated with in situ carcinomas in MAMCs. Stromal
deposition of both proteoglycans was related to higher expression of ERa and PR in tumor cells only in MAMCs.
Conclusions: The specific accumulation of versican in breast tissue with high MD and MAMCs only in the
presence of malignant transformation and its association with the aggressiveness of the tumor suggests its
possible use as molecular marker in non-palpable breast carcinomas.
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Breast carcinoma is considered to be one of the main
causes of cancer mortality. Assessment of the risk of
development of invasive breast cancer has become a sig-
nificant problem. In the last decade, screening programs
have been intensified since mammographic screening
significantly contributes on breast cancer mortality [1,2].
The major aim of these programs is the detection of
breast carcinomas in earlier and probably better curable
stage [3]. In the past 20 years, concomitant with the
wide use of screening mammography, the incidence of
ductal carcinoma in situ (DCIS) has risen dramatically,
in asymptomatic women to 20-25% of all screening
detected breast cancers [4]. Therefore, the mammogra-
phically diagnosed non-palpable breast carcinomas are
increasingly considered as a unique entity of major clini-
cal interest. Non-palpable breast carcinomas consists a
heterogeneous group of lesions with variable findings
and different prognosis. Mammographically detected
density is a risk factor for breast cancer and is attributed
to alterations in the composition of breast tissue [5,6].
Previous studies seeking to understand the biological
basis of mammographic density (MD) have focused on
associations with epithelial and stromal changes [7,8].
Another mammographic finding of higher risk than tis-
sue density for breast cancer is malignant-appearing
microcalcifications (MAMCs), which are associated with
in situ and invasive breast carcinomas in asymptomatic
women [9]. MAMCs are the primary indication for
approximately 50% of the breast biopsies carried out for
non-palpable mammographic abnormalities, although
they do not always represent malignancy [10].
A wide range of prognostic markers have been proposed
for non-palpable breast carcinomas. The clinically avail-
able markers such as histological type, size, auxiliary node
involvement and cytological grading are not sufficient,
considering the biological complexity of this clinical entity
[11]. Several biological markers such as estrogen receptor
alpha (ERa), progesterone receptor (PR), and the ErbB
family of receptor tyrosine kinases have been evaluated by
means of immunohistochemistry in non-palpable breast
carcinomas and found to correlate with mammographic
findings of higher risk such as MAMCs [12,13]. Estrogens
contribute to the initiation and promotion of cancer
through triggering the proliferation of breast epithelium
and stroma. Consequently they increase the changes of
mutation in rapidly proliferating epithelium and those
effects accumulate with increasing cumulative exposure to
estrogens [14]. The over-expression of c-erbB2 (HER-2/
neu) is associated with more aggressive tumor behavior
[15].
Although breast cancer is a direct manifestation of
alterations in the expression of multiple genes and
cellular pathways within the cancer cell, it is now recog-
nized that perturbations in stromal-epithelial interac-
tions also influence tumorigenesis and progression
through direct effects on growth factor-induced signal-
ing pathways and indirect effects mediated through cell
adhesion and structure [8,16,17].
Several studies have demonstrated abnormal expres-
sion of the matrix-secreted proteoglycans versican and
decorin in various cancer types such as prostate [18,19],
breast [20,21], gastric [22], colorectal [23,24], ovarian
[25], pancreatic [26], laryngeal [27,28] and testicular
tumors [29]. Versican is synthesized mainly by stromal
cells and is capable to regulate tumor cell growth and
motility. Versican may facilitate the local expansion of
cancer cells and, subsequently, the invasion and forma-
tion of distant metastases by decreasing cell-matrix
adhesion, sufficient to promote cancer cell migration
through the extracellular matrix [30-32]. This notion is
supported by observations that relapse in women with
stage I node-negative breast cancer is related to the
level of versican accumulated in peritumoral stroma [21]
and the increased levels of peritumoral versican are also
predictive of poor prognosis in patients with early-stage
prostatic cancer [18]. In contrast, decorin, which is
mainly over-expressed by activated fibroblasts in various
cancer types, is considered to be a tumor suppressor
proteoglycan [18,22-24,26-29,32]. Others have previously
shown that matrix proteoglycans lumican and decorin
a r ea b u n d a n tc o m p o n e n t so fb r e a s tt i s s u es t r o m aa n d
that altered expression of lumican and decorin is asso-
ciated with tumor progression and outcome [33-35].
These proteoglycans are important for stromal integrity
through their implication in fibrillar collagen cross link-
ing. Decorin is also a powerful regulator of growth fac-
tor-mediated signaling [32].
We therefore wished to examine the relationship
between mammographic findings suggestive of malig-
nancy in non-palpable breast carcinomas and the
expression of stromal proteoglycans versican and dec-
orin, to establish whether the increased risk attributed
to these findings might reflect stromal alterations. The
expression of both proteoglycans was correlated with
tumor characteristics and established biomarkers of the
disease to evaluate their implication in breast cancer
biology. Both proteoglycans were accumulated in MD
and MAMCs although decorin was most likely asso-
ciated with tissue fibrosis and matrix deposition. Versi-
can was specifically accumulated in MD and MAMCs in
the presence of malignant transformation and was sig-
nificantly correlated with increased tumor grade and
invasiveness. The over-expression of both proteoglycans
is associated with the presence of ERa and PR in tumor
cells in MAMCs.
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Patient population
This is a retrospective, single-center study conducted at
the University Hospital of Patras, Greece. The conduct
of the study was approved by the institutional review
board of Patras Medical School and written informed
consent was obtained from the patients. Between 1989
and 2002, 310 patients with non-palpable suspicious
breast lesions detected during screening mammography
were evaluated. The median age of the patients was
55 years, (range, 35-74 years) and none of the patients
had previously been screened or shown clinical signs of
breast disease.
Mammography
The standard craniocaudal and lateral views were carried
out in all patients. Mammographic findings requiring
further exploration with breast biopsy were considered
the following: (1) microcalcifications; (2) mass with or
without microcalcifications; (3) architectural distortion
with or without microcalcifications; and (4) asymmetric
density with the greater diameter < 1 cm with or without
microcalcifications [10]. Based on published observations,
we evaluated MAMCs according to their shape (e.g. pleo-
morphic, irregular, fragmented, casting), density (highly
variable), distribution (e.g. clustered) and size (highly
variable) [36].
Breast lesion localization
All patients with suspicious and highly suggestive of malig-
nancy non-palpable breast lesions classified as BI-RADS 4
and BI-RADS 5 underwent pre-operative mammographi-
cally guided breast lesion localization with a Kopan breast
localization needle (19G, 9 cm length) [37].
Immunohistochemistry
Histological examination of the specimens showed 83/310
carcinomas. Immunohistochemical analysis was carried
out in 62 out of 83 carcinomas, on the basis of tissue avail-
ability, 9 normal breast tissues, 14 breast tissues with high
MD and 14 breast tissues with MAMCs without patholo-
gic findings. MAMCs was the prominent finding in 48
cases and 14 cases were characterized by increased MD
without microcalcifications. Tissue sections were obtained
from the files of the Department of Pathology in the Uni-
versity Hospital of Patras. A panel of antibodies was
employed for versican (2-B-1 Seikagaku), decorin (6-B-6
Seikagaku), ERa (6F11 Novocasta), PR (1A6 Novocasta),
c-erbB2 (CB11 Biogenex). Avidin-biotin-peroxidase
complex method (Dako Co., Copenhagen, Denmark)
and microwave antigen retrieval was carried out. Tissue
samples were fixed in 10% buffered formalin and
embedded in paraffin. Serial 5- μm sections were taken
and deparaffinized with xylene and dehydrated with 98%
ethanol. The sections were treated with 1 U/ml chondroi-
tinase ABC for 15 min at 37°C to detach glycosaminogly-
can side chains from the protein core for versican and
decorin staining. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 5 min at room
temperature. Non-specific protein binding of the antibo-
dies was blocked by incubation with 3% normal swine
serum in PBS for 20 min at room temperature. Slides were
incubated with the antibodies diluted in PBS containing
1% normal swine serum for 1 h at room temperature. The
resulting antigen- antibody complexes were visualized by
30 min incubation at room temperature, using appropriate
biotinylated secondary antibodies diluted 1:200 and
the avidin-biotin-peroxidase technique (Dako Co., Copen-
hagen, Denmark). The staining was developed with 3, 3-
diaminobenzidine/hydrogen peroxide for 5 min at room
temperature and slides were counterstained with haema-
toxylin. A positive tissue control and a negative reagent
control (without primary antibody) were run in parallel.
The level of decorin and versican expression was assessed
by semiquantitative scoring devised by Alowami et al., [38]
which includes (i) the overall percentage of the tissue sec-
tion stained positive (0-100%), and (ii) the signal intensity
(4-point scale) for each proteoglycan. The scoring used for
the 4-point scale was: 1, negative or very weak staining; 2,
weak positive; 3, moderate positive; 4, strong positive. The
semiquantitative immunohistochemical (IHC) score for
the expression level for each proteoglycan was provided by
the multiplication of the percentage (0-100) of the tissue
section staining positive by the factor (1-4) corresponding
to the staining intensity of the tissue section. Positivity
scoring for ERa, PR and c-erbB2 was carried out as
described previously [12]. Three independent researchers
randomly evaluated the specimens using this method.
Statistical analysis
Data were analysed using GraphPad Prism (Version 3.0;
GraphPad Software Inc., San Diego, CA, USA). Statistical
analyses were performed using the Mann-Whitney U-test,
Kruskal-Wallis Anova by ranks and linear regression
analysis (Pearson). All tests were two-tailed and statistical
significance was set at P < 0.05.
Results
Mammographic findings
Three hundred and ten patients with suspicious and highly
suggestive of malignancy mammographically found non-
palpable breast lesions, classified as BI-RADS 4 and BI-
RADS 5, who underwent mammographically guided nee-
dle excision biopsy were evaluated. Eighty-three out of 310
(26.8%) non-palpable breast lesions proved histologically
to be carcinomas. Histological subtypes were 46/83 ductal
invasive carcinomas (55.5%), 31/83 ductal in situ carcino-
mas (37.3%) and 6/83 lobular invasive carcinomas (7.2%).
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mass, density or distortion were detected in 65 out of
83 (78.3%) patients with non-palpable breast carcinoma
(Table 1). Immunohistochemistry was performed in 62/83
carcinomas on the basis of tissue availability, 9 normal
breast tissues, 14 breast tissues with high MD and 14
breast tissues with MAMCs without pathologic findings.
The median age of the patients was 58 years (range, 41-74
years). Non-palpable breast carcinomas were divided in
two groups according to their mammographic findings,
one which is characterized by the presence of increased
MD, mass and/or distortion (14/62) (Figure 1A) and the
other characterized by the presence of MAMCs as an
isolated finding or in combination with a mass, density or
distortion (48/62) (Figure 1B-D). The expression of
proteoglycans was evaluated in breast carcinomas and
compared to normal breast tissues with identical mammo-
graphic findings.
Decorin and versican expression and association with
mammographic appearance
In normal breast, staining for decorin was observed in
the interstitial connective tissue surrounding the glands
(Figure 2A), whereas negligible deposits of versican were
also identified in stroma surrounding normal glands
(Figure 2B). Interestingly, there was a marked stromal
Table 1 Mammographic appearance of histologically proven non-palpable breast carcinomas
Histology/Mammography Invasive ductal carcinoma In situ ductal carcinoma Invasive lobular carcinoma Total
Microcalcifications 20 19 1 40
Density, mass or distortion 12 3 3 18
Density, mass or distortion and microcalcifications 14 9 2 25
Total 46 31 6 83
A B
C D
Figure 1 Representative mammographic images of non-palpable breast carcinomas. (A), High density with indistinct margins classified as
BI-RADS 4. (B), High density with indistinct margins and microcalcifications classified as BI-RADS 4. (C), Linear microcalcifications, BI-RADS 4 and
(D), pleomorphic multifocal calcifications, BI-RADS 4.
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ductal epithelial proliferations and in situ tumor compo-
nents (Figure 2C and 2D). This was more diffusely
distributed in the case of decorin, whereas versican
staining was limited to the immediate proximity of the
basement membrane. Prominent immunostaining for
versican and decorin was observed in stroma associated
with malignant areas of sectioned breast tissue. In the
majority of patients with breast cancer, increased stain-
ing for versican and decorin was found, in the peritu-
moral and intratumoral stroma. In the central areas of
malignant tumors, the staining was generally strong for
both decorin and versican. The staining intensity for
both proteoglycans was strong but varied considerably
at the periphery of the same tumors. The expression of
decorin and versican differed greatly in carcinomas with
increased MD (Figure 3A and 3B) and carcinomas with
MAMCs (Figure 3C and 3D). The expression of decorin
was markedly elevated in breast carcinomas and normal
tissues that are characterized by increased MD and
MAMCs (Figure 3A, C, E and 4A). The overall expres-
sion of decorin was significantly higher in carcinomas
and normal tissues with MAMCs (median ± SE: 91.5 ±
13.6 for carcinomas and 96.0 ± 18.9 for normal tissues)
compared to tissues with increased MD (median ± SE:
46.5 ± 17.4 for carcinomas and 43.0 ± 13.7 for normal
tissues) and normal tissue (median ± SE: 20.5 ± 2.5)
(Figure 4A). No statistically significant differences were
observed between sub-groups of carcinoma and normal
tissues characterized by the presence of MD and
MAMCs, indicating that decorin accumulation in the
stroma may not correlate specifically with malignant
A B
C D
Decorin Versican
Normal Breast
Breast DCIS
Figure 2 Immunohistochemical localization of decorin and versican in normal breast and breast carcinomas. Normal breast tissue (A and
B) and non-palpable breast DCIS (C and D) stained for decorin (A and C) and versican (B and D). Bars, 100 μm.
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Page 5 of 13transformation (Figure 4A). In contrast, the expression
of versican was significantly higher only in carcinomas
showing increased MD and MAMCs compared to nor-
mal tissues with identical mammographic findings
(Figure 3B, D, F and 4B). The overall expression of ver-
sican was significantly higher in carcinomas with
MAMCs (median ± SE: 42.0 ± 9.1 for carcinomas and
14.0 ± 5.8 for normal tissues) compared to tissues with
A B
C D
F E
Decorin Versican
Breast carcinoma with MD
Breast carcinoma with MAMCs
Normal breast with MAMCs
Figure 3 Stromal deposition of decorin and versican in normal breast and breast carcinomas with MD and MAMCs. Non-palpable breast
carcinomas associated with high MD (A and B), mammographically found MAMCs (C and D) and normal breast tissue associated with MAMCs (E
and F) stained for decorin (A, C and E) and versican (B, D and F). Bars, 100 μm.
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Page 6 of 13increased MD (median ± SE: 22.5 ± 10.1 for carcinomas
and 11.0 ± 4.4 for normal tissues) and normal tissue
(median ± SE: 10.0 ± 2.0) (P < 0.01) (Figure 4B).
Correlation between decorin and versican expression and
tumor characteristics
Higher expression of decorin in the tumor stroma was
found to associate with in situ breast cancer only in
patients with MAMCs (P = 0.01) (Figure 5A-D). On the
other hand the elevated expression of versican in the
tumor stroma was strongly correlated with higher tumor
grade and invasiveness in patients with MD and
MAMCs (Figure 6A-D). The accumulation of decorin
was significantly related to higher expression of ERa
(P =0 . 0 2 )a n dP R( P < 0.01) in tumor cells only in
patients with MAMCs (Figure 7A-D). Similarly, the
expression of versican is significantly associated with
higher expression of ERa (P < 0.01) and PR (P < 0.01)
in tumor cells only in patients with MAMCs (Figure 7E-
H). c-erbB2 expression was found in 1/14 carcinoma
with MD and 13/48 of patients with MAMCs. The
expression of both proteoglycans was not related to the
presence of c-erbB2 in tumor cells in patients with MD
and MAMCs (figure not shown).
Discussion
An improved understanding of factors influencing
changes in MD and the formation of MAMCs would
improve their value and practical application in risk
assessment in non-palpable breast cancer. Although
both MD and microcalcifications have been shown to be
influenced by various parameters [7,8,12,13,39,40], the
biological basis underlying these tissue alterations is
largely unknown [41]. Studies have shown that both
stromal architecture and composition can exert an
important influence on normal epithelial homeostasis
[16,17,42], and somatic mutations can be identified in
the stromal compartment of breast tumors indepen-
dently of mutations in the neoplastic epithelium [43,44].
These observations are in accordance with the concept
that stromal alterations might not always be ‘reactive’
but might sometimes play an initial ‘landscaping’ role in
breast carcinogenesis, as has been proposed for the
colon [45]. Several studies have shown the relationship
between increased MD and specific epithelial lesions
[7,8,39,46], whereas others have also noted a close asso-
ciation with stromal changes and suggest that MD
correspond more directly to alterations in stromal com-
position including decorin [8,38,40]. In this study, we
found a significant accumulation of decorin in normal
breast tissues that are characterized by increased MD
and MAMCs. A similar increase in decorin expression
was noticed to the tumor stroma in non-palpable breast
carcinomas with high MD and MAMCs. Decorin
directly binds to collagen and affects fibrillogenesis and
fibril spacing that are important aspects for stromal
architecture and properties [32,47]. Taken into consid-
eration our data and the previous observations that
increased MD is associated with higher collagen density
and extended fibrosis [38], it is likely that the deposition
of decorin in MD and MAMCs might be associated
with tissue fibrosis and matrix deposition. Furthermore,
the observation that decorin levels are significantly
Normal MD MAMCs
P=0.64
P=0.77
P<0.01 *
(A)
Normal MD MAMCs
P=0.01
P=0.02
P<0.01 *
(B)
Figure 4 Elevated expression of versican associates with MD
and MAMCs in breast carcinomas. Correlation of decorin (A) and
versican (B) immunostaining in normal breast tissue, and normal and
carcinoma tissues with mammographically detected high MD and
MAMCs. Immunohistochemical (IHC) score was estimated as
described in materials and methods. Bars represent the median value
within each category. Differences between sub-groups (normal and
cancer tissues with identical mammographic findings) were analyzed
by Mann-Whitney U-test. (*) Statistically significant accumulation of
decorin (A) and versican (B) in breast carcinomas associated with
high MD and MAMCs [correlation of sub-groups: normal breast
tissue, breast carcinoma with MD and breast carcinoma with MAMCs
marked with black dots (￿) using Kruskal-Wallis Anova].
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with MAMCs suggests that up-regulation of decorin
prevents tumor spread. This is consistent with the
observation that decorin inhibits various signaling cas-
cades of the ErbB family of receptor tyrosine kinases
[32,47] and low levels of decorin expression are asso-
ciated with poor outcome in primary invasive tumors
[34].
In contrast, the expression of versican is specifically up-
regulated only in breast tissues with high MD and
MAMCs, which are associated with malignant transforma-
tion. The deposition of versican in tumor stroma is signifi-
cantly higher in MAMCs, a mammographic finding that is
associated with higher risk for breast cancer than
increased MD alone. The accumulation of versican in
non-palpable carcinomas is related to higher tumor grade
and the presence of invasive disease in lesions of both MD
and MAMCs. This supports further the notion of a posi-
tive role for versican in tumor growth and progression in
breast cancer. The increased accumulation of versican in
tumor stroma by mammary fibroblasts is correlated with
relapse in women with node-negative breast cancer [21].
Additional evidences in early-stage prostatic cancer [18]
and ovarian cancer [25] supports the view that versican
deposition is associated with progression of disease. Versi-
can is thought to be an anti-adhesion molecule and this
activity resides in the G1 domain of versican [30-32]. The
interaction of versican with several binding molecules
such as hyaluronan and CD44 promotes expansion of the
pericellular matrix [48]. These complexes increase the vis-
coelastic nature of the pericellular matrix, creating a highly
malleable extracellular environment which supports a cell
shape change necessary for cancer cell proliferation and
migration [30-32]. Furthermore, versican could influence
cell proliferation by acting as a mitogen itself through the
epidermal growth factor (EGF) sequences in the G3
domain [30,32], whereas versican G3 domain appears to
be important in local and systemic tumor invasiveness of
human breast cancer affecting both tumor cell survival
and spread but also angiogenesis [49].
In postmenopausal women, MD is directly associated
with circulating levels of estradiol [50] supporting a role of
Breast carcinomas with MD
P=0.12
Breast carcinomas with MAMCs
Grade I Grade II/III In situ Invasive
Grade I Grade II/III In situ Invasive
(A) (B)
(C) (D)
P=0.36
P=0.27 P=0.01
Figure 5 Accumulation of decorin correlates with in situ breast carcinomas in patients with MAMCs. Correlation between decorin
immunostaining and tumor grade (A and C) and invasiveness (B and D) in breast carcinoma with high MD (A and B) and MAMCs (C and D).
Differences between sub-groups were analyzed by Mann-Whitney U-test.
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aromatase the key enzyme converting testosterone to
estradiol is increased in mammographically dense tissue in
both the stroma and epithelium as demonstrated by
immunohistochemistry [51]. We found that the elevated
expression of decorin and versican by stromal fibroblasts
in non-palpable breast carcinomas with MAMCs is posi-
tively correlated with the higher expression of ERa and PR
by tumor cells. The expression of estrogen receptors in
tumor cells most likely associate with increased levels of
estrogens that regulate the growth of tumor cells in hor-
mone-dependent breast cancer. Estradiol has found to
play a key role in the expression of proteoglycans in breast
cancer cells via its action to ERa [52]. Published data
demonstrate that the biosynthesis of both proteoglycans is
positively regulated by estrogens in osteoblastic cells [53]
and normal endometrial stromal cells [54]. Possibly estro-
gens mainly produced locally by stromal fibroblasts in
early stages of breast carcinogenesis drive through para-
crine action tumor growth and through autocrine
mechanisms the biosynthesis of versican and decorin by
themselves. The expression of these proteoglycans is also
regulated by various growth factors and cytokines present
in increased amounts in the microenvironment of breast
cancer lesions [30-32].
MAMCs are suggested to be a consequence of an active
secretory process by the tumor cells [55]. Malignant
mammary cells could express matrix molecules that
would create an appropriate microenvironment to trigger
calcifications by hydroxyapatite formation [55]. Benign or
proliferative breast disease is associated with the deposi-
tion of oxalate calcifications, whereas hydroxyapatite
crystals are related to invasive breast cancer [55]. Proteo-
glycans bind to hydroxyapatite and are involved in the
calcification process acting either as promoters or inhibi-
tors [56,57]. Decorin and biglycan are involved in the
mineralization process and are required for normal bone
development [58]. One hypothesis for the role of decorin
in mineralization is that its modulation of collagen fibril-
logenesis in the extracellular matrix indirectly affects
P<0.01 (A) (B) P<0.01
Grade I Grade II/III In situ Invasive
Grade I Grade II/III In situ Invasive
(C) (D) P=0.01 P=0.02
Breast carcinomas with MAMCs
Breast carcinomas with MD
Figure 6 Accumulation of versican correlates with higher tumor grade and invasive disease in breast carcinomas. Correlation between
versican immunostaining and tumor grade (A and C) and invasiveness (B and D) in breast carcinoma with high MD (A and B) and MAMCs (C
and D). Differences between sub-groups were analyzed by Mann-Whitney U-test.
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Page 9 of 13Decorin IHC score Decorin IHC score
Decorin IHC score Decorin IHC score
Versican IHC score Versican IHC score
Versican IHC score Versican IHC score
(A) (B)
(C) (D)
(E) (F)
(G) (H)
P=0.45
P=0.24
P<0.01
P=0.02
P<0.01
P=0.33
P=0.43
P<0.01 
Breast carcinomas with MAMCs Breast carcinomas with MD
Figure 7 Elevated expression of decorin and versican associates with higher expression of ERa a n dP Ri nb r e a s tc a r c i n o m a sw i t h
MAMCs. Correlation between decorin (A-D) and versican (E-H) immunohistochemical score (IHC) and percentage of tumor cells positive for ERa
(A, B, E and F) and PR (C, D, G and H) in breast carcinoma with high MD (A, C, E and G) and MAMCs (B, D, F and H). Two-sided P-values were
obtained by linear regression analysis (Pearson correlation).
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sion is also associated with intracellular calcification in
epithelial cells [60]. The intracellular calcification may be
a potential origin for pathologic calcification in breast
cancer. Hydroxyapatite crystals stimulate mitogenesis
and up-regulate the production of a variety of matrix
metalloproteinases in malignant mammary cells and
fibroblasts that mediate the degradation of the basement
membrane and the surrounding matrix thus leading to
the formation of distant metastases [61-63].
A possible scenario for the involvement of both proteo-
glycans in breast cancer progression may involve the accu-
mulation of both versican and decorin by stromal
fibroblasts in response to estrogens, growth factors and
cytokines. The accumulated versican in the tumor stroma
supports tumor growth and metastasis. Decorin is directly
involved in the formation of a collagenous rich stroma
associated with MD and may together with versican facili-
tate the formation of hydroxyapatite microcalcifications.
In this process, stromal fibroblasts may be also involved.
They over-express versican and decorin that may promote
intracellular calcification. Hydroxyapatite crystals together
with growth factors produced by cancer cells are capable
to trigger cancer and stromal cell proliferation and up-reg-
ulation of synthesis of matrix degrading enzymes facilitat-
ing cancer cell spread.
Conclusion
The results of this study suggest that the accumulation of
versican in the tumor stroma is correlated with high MD
and the formation of MAMCs associated with malignant
transformation. The highest accumulation of versican was
found in MAMCs, a mammographic finding of higher risk
for malignancy in non-palpable breast lesions. The over-
expression of versican was also significantly associated
with the elevated expression of ERa and PR in tumor
cells, higher tumor grade and invasiveness. These data
suggest a key role for versican in disease progression and
its possible use as molecular biomarker in non-palpable
breast cancer.
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